MSD in the UK
Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc., is a leading global healthcare company headquartered in Great Britain. Established in 1891, MSD has made significant strides in the pharmaceutical industry, focusing on innovative medicines, vaccines, and animal health products. With major operational regions across Europe, the Middle East, and Africa, MSD is committed to improving health outcomes through research and development. The company is renowned for its core products, including groundbreaking treatments in oncology, infectious diseases, and vaccines, which are distinguished by their efficacy and safety profiles. MSD's dedication to scientific advancement has positioned it as a key player in the UK market, with notable achievements in drug development and a strong commitment to public health initiatives.
DitchCarbon Score
How does MSD in the UK's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MSD in the UK's score of 34 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MSD in the UK's reported carbon emissions
In 2022, MSD in the UK reported total carbon emissions of approximately 7,124,000 kg CO2e for Scope 1, 2, and 3 combined. The breakdown includes about 712,400,000 kg CO2e from Scope 1, 218,800,000 kg CO2e from Scope 2, and a significant 6,787,100,000 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions encompass various categories, with purchased goods and services contributing approximately 5,263,100,000 kg CO2e. For the previous year, 2021, MSD's emissions in the UK totalled about 31,190,000 kg CO2e, with Scope 1 emissions at approximately 4,330,000 kg CO2e, Scope 2 at around 1,390,000 kg CO2e, and Scope 3 emissions reaching about 25,470,000 kg CO2e. The Scope 3 emissions in 2021 also highlighted significant contributions from upstream transportation and distribution, which accounted for approximately 11,020,000 kg CO2e. MSD's emissions data is cascaded from its parent company, Organon Pharma (UK) Limited, and reflects a corporate family relationship. However, there are currently no specific reduction targets or climate pledges documented for MSD in the UK, indicating a potential area for future commitment and improvement in their climate strategy. Overall, MSD's emissions profile illustrates the substantial impact of Scope 3 emissions, particularly from purchased goods and services, underscoring the importance of addressing these areas in their climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | |
|---|---|---|
| Scope 1 | 728,600,000 | 000,000,000 |
| Scope 2 | 294,600,000 | 000,000,000 |
| Scope 3 | 6,380,500,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MSD in the UK is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
